MONOCYTE CHEMOTACTIC PROTEIN-3 (MCP3) INTERACTS WITH MULTIPLE LEUKOCYTE RECEPTORS - BINDING AND SIGNALING OF MCP3 THROUGH SHARED AS WELL ASUNIQUE RECEPTORS ON MONOCYTES AND NEUTROPHILS
Ll. Xu et al., MONOCYTE CHEMOTACTIC PROTEIN-3 (MCP3) INTERACTS WITH MULTIPLE LEUKOCYTE RECEPTORS - BINDING AND SIGNALING OF MCP3 THROUGH SHARED AS WELL ASUNIQUE RECEPTORS ON MONOCYTES AND NEUTROPHILS, European Journal of Immunology, 25(9), 1995, pp. 2612-2617
The diversity of monocyte chemotactic protein (MCP)3 target cell types
, as well as the capacity of MCP3 to desensitize leukocyte responses t
o other CC chemokines, suggested that MCP3 may interact with multiple
CC chemokine receptors. The purpose of this study is to establish how
MCP3 binds and activates monocytes and neutrophils. We show that human
monocytes exhibit high-affinity binding for I-125-MCP3 with an estima
ted Kd of 1-3 nM and about 10 000 binding sites/cell. The binding of I
-125-MCP3 to monocytes was progressively less well competed by CC chem
okines macrophage inflammatory protein (MIP)1 alpha (Kd = 5-10 nM), RA
NTES (Kd = 5-10 nM), MCP1 (monocyte chemoattractant and activating fac
tor, or MCAF) (Kd = 60 nM) and MIP1 beta (Kd > 100 nM). On the other h
and, unlabeled MCP3 displaced the binding of radiolabeled MIP1 alpha,
RANTES, MCP1 and MIP1 beta as effectively as the isologous CC chemokin
es. In agreement with the binding data, pretreatment of monocytes with
MCP3 completely desensitized the calcium flux in response to MIP1 alp
ha and RANTES. However, MIP1 alpha and RANTES failed to desensitize th
e response of monocytes to MCP3. MCP3 and MCP1 partially desensitized
each other's effects on monocytes. These binding and cross-desensitiza
tion results suggest that MCP3 binds and signals through other binding
sites in addition to those shared with MIP1 alpha, RANTES and MCP1, T
he unidirectional competition for MIP1 beta binding and signaling by M
CP3 suggests the existence of an as-yet unidentified site for MCP3 sha
red with MIP1 beta. The existence of another unique binding site(s) fo
r MCP3 was further shown by the failure of any of the other CC chemoki
nes to compete effectively for MCP3 binding on neutrophils. MCP3 in ou
r study was also the only human CC chemokine that consistently chemoat
tracted neutrophils. These results suggest that MCP3 is a ligand that
can bind and activate a broad range of target cells through receptors
shared by other CC chemokines as well as its own receptor.